[Federal Register Volume 69, Number 65 (Monday, April 5, 2004)]
[Notices]
[Page 17722]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-7786]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]


Vaso Active Pharmaceuticals, Inc.; Order of Suspension of Trading

April 4, 2004.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Vaso Active Pharmaceuticals, Inc. (``VAPH'') because of questions 
regarding the accuracy of assertions by VAPH and by others, in press 
releases, its annual report, its registration statement and public 
statements to investors concerning, among other things: (1) FDA 
approval of certain key products, and (2) the regulatory consequences 
of the future application of their primary product.
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of the above-listed company.
    Therefore, it is ordered, pursuant to section 12(k) of the 
Securities Exchange Act of 1934, that trading in the above-listed 
company is suspended for the period from 9:30 a.m. EST on Thursday, 
April 1, 2004 through 11:59 p.m. EDT, on Thursday, April 15, 2004.

    By the Commission.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 04-7786 Filed 4-1-04; 1:48 pm]
BILLING CODE 8010-01-P